Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Why Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?
12:47pm, Thursday, 03'rd Jun 2021
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
8 Stocks With The Highest Short Interest
03:00pm, Wednesday, 02'nd Jun 2021
Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding sh
ESPERION Appoints Sheldon Koenig as President and CEO
09:01am, Monday, 17'th May 2021
-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served a
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascu
Esperion: A Change In Plans After A Disappointing Q1 Earnings
08:34am, Thursday, 06'th May 2021
Esperion: A Change In Plans After A Disappointing Q1 Earnings
Why Esperion Therapeutics Plummeted Nearly 22% Today
06:30pm, Wednesday, 05'th May 2021
It was all about the earnings.
Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines
03:38pm, Wednesday, 05'th May 2021
Esperion Therapeutics Inc (NASDAQ: ESPR) reported a first-quarter EPS loss of $3.50, compared to $2.84 a year ago, which missed the analyst consensus estimate of $2.52. The company reported quarte
Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales
11:39am, Wednesday, 05'th May 2021
Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.
Where Esperion Therapeutics Stands With Analysts
09:47am, Wednesday, 05'th May 2021
Analysts have provided the following ratings for Esperion Therapeutics (NASDAQ:ESPR) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 0 1 Somewhat Bullish 2 0 0
Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q1 2021 Results - Earnings Call Transcript
09:44pm, Tuesday, 04'th May 2021
Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q1 2021 Results - Earnings Call Transcript
ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
04:01pm, Tuesday, 04'th May 2021
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price –
Esperion Secures $50 Million Funding from Oberland Capital
04:07pm, Monday, 26'th Apr 2021
ANN ARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to pro
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
04:02pm, Monday, 26'th Apr 2021
– Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments – – Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion – – D
Esperion to Report First Quarter 2021 Financial Results May 4, 2021
04:01pm, Monday, 12'th Apr 2021
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesd
NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study
04:05pm, Wednesday, 17'th Mar 2021
- Results of bempedoic acid, ezetimibe and atorvastatin triple therapy study published in March issue of Atherosclerosis -
